“Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies”, J of Skin, vol. 4, no. 5, p. s46, Sep. 2020, doi: 10.25251/skin.4.supp.46.